Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/3030% below fair value
$6.08+0.17 (+2.88%)
Close on Nov 13, 2026Market cap $11.71MP/E –Yield –
Bolt Biotherapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Bolt Biotherapeutics's price to sales ratio was 2.6× on Nov 11, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 1.0× to 303.5×, with a median of 3.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.6× | +0.5 |
| 2025 | Dec 31, 2025 | 2.0× | −0.1 |
| 2024 | Dec 31, 2024 | 2.1× | −3.8 |
| 2023 | Dec 29, 2023 | 5.9× | −4.2 |
| 2022 | Dec 30, 2022 | 10.1× | −196.0 |
| 2021 | Apr 30, 2021 | 206.2× | – |
See a number that looks wrong?